Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

In response to: Steatotic liver disease-know your enemies

Michael H. Le, Linda Henry, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(2):284-286. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0108

View: 653 Download: 15

Original Article

Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(2):235-246. Published online January 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0485

View: 1681 Download: 176 Crossref: 3

Letter to the Editor

Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon

Clin Mol Hepatol. 2024;30(1):118-120. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0472

View: 1574 Download: 45 Web of Science: 1 Crossref: 1

Review

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra

Clin Mol Hepatol. 2023;29(Suppl):S286-S301. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0392

View: 5055 Download: 244 Web of Science: 9 Crossref: 9

Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management

Anja Geerts, Sander Lefere

Clin Mol Hepatol. 2023;29(Suppl):S276-S285. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0373

View: 3314 Download: 122 Web of Science: 4 Crossref: 4

Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease

Georg Semmler, Christian Datz, Michael Trauner

Clin Mol Hepatol. 2023;29(Suppl):S244-S260. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0364

View: 5147 Download: 293 Web of Science: 6 Crossref: 7

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne

Clin Mol Hepatol. 2023;29(Suppl):S157-S170. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0348

View: 3556 Download: 294 Web of Science: 12 Crossref: 13

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 4224 Download: 223 Web of Science: 12 Crossref: 14

Interaction between sarcopenia and nonalcoholic fatty liver disease

Sae Kyung Joo, Won Kim

Clin Mol Hepatol. 2023;29(Suppl):S68-S78. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0358

View: 4445 Download: 285 Web of Science: 16 Crossref: 17

MAFLD: How is it different from NAFLD?

Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George

Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0367

View: 11117 Download: 961 Web of Science: 36 Crossref: 51

Letter to the Editor

Letter regarding “Risk factors in nonalcoholic fatty liver disease”

Abhijit Pratap, Umesh More, Pradnya Phalak, Anita Deshmukh

Clin Mol Hepatol. 2023;29(4):1046-1047. Published online August 22, 2023

DOI: https://doi.org/10.3350/cmh.2023.0268

View: 1337 Download: 35 Web of Science: 1 Crossref: 1

Editorial

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials

Ming-Lun Yeh, Ming-Lung Yu

Clin Mol Hepatol. 2023;29(4):969-972. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0359

View: 1785 Download: 142 Web of Science: 3 Crossref: 3

The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B

Xianhua Mao, Lung Yi Mak, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(3):690-692. Published online May 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0173

View: 1756 Download: 80 Web of Science: 1 Crossref: 1

Original Article

Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma

Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, Sulki Park, Nicole E. Rich, Mazen Noureddin, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2023;29(2):453-464. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0450

View: 3224 Download: 114 Web of Science: 2 Crossref: 2

Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease

Kathryn Jane Waller, Hajar Saihi, Wenhao Li, James Hallimond Brindley, Anja De Jong, Wing-kin Syn, Conrad Bessant, William Alazawi

Clin Mol Hepatol. 2023;29(2):417-432. Published online November 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0205

View: 4640 Download: 164 Web of Science: 2 Crossref: 4

Editorial

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Lynna Alnimer, Mazen Noureddin

Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0104

View: 2392 Download: 79 Web of Science: 2

Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed

Philipp Kasper, Münevver Demir, Hans-Michael Steffen

Clin Mol Hepatol. 2023;29(2):390-393. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0059

View: 2323 Download: 53 Web of Science: 2 Crossref: 2

Original Article

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B

Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kwang-il Kim, Soo-Hwan Kim, Kyu Sung Rim, Seong Gyu Hwang

Clin Mol Hepatol. 2019;25(1):52-64. Published online October 23, 2018

DOI: https://doi.org/10.3350/cmh.2018.0040

View: 8357 Download: 338 Web of Science: 73 Crossref: 70

Review

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs

Stephen Caldwell

Clin Mol Hepatol. 2017;23(2):103-108. Published online May 10, 2017

DOI: https://doi.org/10.3350/cmh.2017.0103

View: 11926 Download: 472 Web of Science: 30 Crossref: 30

Original Article

Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease

Min-Sun Kwak, Donghee Kim, Goh Eun Chung, Seung Joo Kang, Min Jung Park, Yoon Jun Kim, Jung-Hwan Yoon, Hyo-Suk Lee

Clin Mol Hepatol. 2012;18(4):383-390. Published online December 21, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.4.383

View: 14494 Download: 119 Crossref: 81

5

Nonalcoholic Steatohepatitis

So-Young Jin

Clin Mol Hepatol. 2006;12(3):455-459. Published online January 1, 2000

View: 2540 Download: 20

2

Insulin Resistance in Non-Alcoholic Fatty Liver Disease

Jeong Hyun Park

Clin Mol Hepatol. 2006;12(1):16-30. Published online January 1, 1970

View: 2877 Download: 27

3

The Prevalence of Metabolic Syndrome in Patients with Nonalcoholic Fatty Liver Disease

Ki Won Moon, M.D., Joung Muk Leem, M.D., Sang Seok Bae, M.D., Ki Man Lee, M.D., Seok Hyung Kim, M.D.*, Hee Bok Chae, M.D., Seon Mee Park, M.D. and Sei Jin Youn, M.D.

Clin Mol Hepatol. 2004;10(3):197-206. Published online January 1, 1970

View: 3082 Download: 58

1 |

Viewed By 5171	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5031	MAFLD: How is it different from NAFLD?
Viewed By 4976	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3658	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3624	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 51	MAFLD: How is it different from NAFLD?

Search